2/123



↑AFFIX CUSTOMER NO. LABEL

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

# UTILITY APPLICATION AND FEE TRANSMITTAL §(1.53(b))

Commissioner for Patents **Box Patent Application** Washington, D.C. 20231

Sir:

The His Can

L.

1

٥١

 Transmitted herewith for filing is the patent application of

Inventor(s) names and addresses:

- (1) Francis Michon 4401 Rosedale Ave Bethesda, MD 20814
- (2) Samuel Moore 7425 Brandenburg Circle Sykesville, MD 21784
- (3) Maryline Laude-Sharp 16721 Gooseneck Terrace Olney, MD 20832
- (4) Milan Blake 8521 Beaufort Dr. Fulton, MD 20759

For: Immunogenic Compositions of Low Molecular Weight Hyaluronic Acid and Methods To Prevent, Treat and Diagnose Infections and Diseases Caused by Group A and Group C Streptococci

	Enclosed Are:		
1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	1	page(s) of specification page(s) of Abstract page(s) of claims sheets of  Formal  Informal drawings page(s) of Declaration and Power of Attorney	
		<ul> <li>✓ Unsigned</li> <li>Newly Executed</li> <li>Copy from prior application</li> <li>Deletion of inventors including Signed Statement under 37 C.F.R. §1.63(d)(2)</li> </ul>	
		REQUEST AND CERTIFICATION UNDER 35 U.S.C. §122(b)(2)(B)(i) (form PTO/SB/35)  As indicated on the attached Request and Certification, Applicant(s) certify that the invention disclosed in the attached application HAS NOT and WILL NOT be the subject of an application filed in another country, or under a multilateral agreement, that requires an application at eighteen months after filing. Applicant(s) therefore request(s) that the attached application NOT be published under 35 U.S.C. §122(b).	
		Incorporation by Reference:  The entire disclosure of the prior application, from which a copy of the combined Declaration and Power of Attorney is supplied herein, is considered as being part of the disclosure of the accompanying application and is incorporated herein by reference.	
		Deletion of Inventors (37 C.F.R. §1.63(d) and §1.33(b)  Signed statement attached deleting inventor(s) named in the prior application serial no.	
ļ-k		Microfiche Computer Program (Appendix)	
		page(s) of Sequence Listing computer readable disk containing Sequence Listing Statement under 37 C.F.R. §1.821(f) that computer and paper copies of the Sequence Listing are the same	
		Assignment Papers (assignment cover sheet and assignment documents)  A check in the amount of \$40.00 for recording the Assignment  Charge the Assignment Recordation Fee to Deposit Account No. 13-4500, Order  No  Assignment Papers filed in the parent application Serial No.	
		Certification of chain of title pursuant to 37 C.F.R. §3.73(b)	

	•
	Priority is claimed under 35 U.S.C. §119 for: Application No(s), filed, in(country).
	Certified Copy of Priority Document(s) []  filed herewith filed in application Serial No, filed  English translation document(s) [] filed herewith filed in application Serial No, filed
	Priority is claimed under 35 U.S.C. §119(e) for: Provisional Application No, filed
	Information Disclosure Statement
	Copy of [] cited references  PTO Form-1449  References cited in parent application Serial No, filed
The first also also the first that the first time the first time that the first time that the first time that the first time time the first time time time time time time time tim	Related Case Statement under 37 C.F.R. §1.98(a)(2)(iii)  A copy of related pending U.S. Application(s) Serial No(s):, filed, respectively, is attached hereto.  A copy of related pending U.S. Application(s) entitled,, filed to inventor(s), respectively, is attached hereto.  A copy of each related application(s) was submitted in parent application serial no, filed
	Preliminary Amendment  Return receipt postcard (MPEP 503)
	This is a continuation divisional continuation-in-part of prior application to which priority under 35 U.S.C. §120 is claimed.
	Cancel in this application original claims of the parent application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)  A Preliminary Amendment is enclosed. (Claims added by this Amendment have been properly numbered consecutively beginning with the number following the highest numbered original claim in the prior application).

4
d)
U1
Ц
IJ
đ١
ij.
Ę)
LT:
H
<b>ļ</b> uk

	The status of the parent application is as follows:  A Petition for Extension of Time and a Fee therefor has been or is being filed in the parent application to extend the term for action in the parent application until
	A copy of the Petition for Extension of Time in the co-pending parent application is attached.
	No Petition for Extension of Time and Fee therefor are necessary in the co-pending parent application.
	Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.
	Transfer the drawing(s) from the parent application to this application
April 1915 April	Amend the specification by inserting before the first line the sentence:  This is continuation divisional continuation-in-part of co-pending application  Serial No, filed

, CALCOLATION 6	OF APPLICATION FEE	Number Extra	Rate	Basic Fee \$710.00/355.00
Fotal Claims	33-20=	14x	\$18.00/ \$9.00	\$ 252.00
Independent Claims	2- 3=	0x	\$80.00/ \$40.00	\$ 0
Multiple Dependent Claims		If marked, add fee of \$270.00 (\$135.00)		\$ 270.00
Numbre Depende	nt Oldma		TOTAL:	\$ 1232.00

	Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith \$
	A check in the amount of \$ in payment of the application filing fees is attached.
$\boxtimes$	Charge fee to Deposit Account No. <u>13-4500</u> , Order No. <u>1758-4050</u> . A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, including all extension of time fees pursuant to 37 C.F.R. § 1.17 for maintaining copendency with the parent application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 1758-4050. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted, MORGAN & FINNEGAN, L.L.P.

Dated: May 11, 2001

By: Damyl H Stemma

Darryl H. Steensma

Darryl H. Steensma Registration No. <u>43,155</u>

Correspondence Address: MORGAN & FINNEGAN, L.L.P.

345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone

(212) 751-6849 Facsimile

### 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Michon, F. et al.

Group Art Unit:

To be assigned

Serial No.:

To be assigned

Examiner:

To be assigned

Filed:

May 11, 2001

For:

Immunogenic Compositions of Low Molecular Weight Hyaluronic Acid and Methods

To Prevent, Treat and Diagnose Infections and Diseases Caused by Group A and

Group C Streptococci

#### **EXPRESS MAIL CERTIFICATE**

Express Mail Label No.:

EL 762620666 US

Date of Deposit:

May 11, 2001

I hereby certify that the following attached paper(s) and/or fee

1. Utility Application (28 pages spec., 1 page Abstract, 5 pages claims, and 15 sheets formal drawings);

2. Declaration and Power of Attorney (7 pages, unexecuted);

3. Utility Application and Fee Transmittal with authorization to charge fees to deposit account No. 13-4500 (5 pages); and

4. Return Receipt Postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to: Box PATENT APPLICATION, Commissioner for Patents, Washington, D.C. 20231.

F Garcia

(Typed or printed name of person mailing papers(s) and/or fee)

(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.

345 Park Avenue

New York, NY 10154-0053

(212) 758-4800 Telephone

(212) 751-6849 Facsimile